"Designing Growth Strategies is in our DNA"
The sickle cell disease treatment market size was valued at USD 1.73 billion in 2021 and is projected to grow from USD 2.25 billion in 2022 to USD 8.75 billion by 2029, at a CAGR of 21.4% during the forecast period. Based on our analysis, the global sickle cell disease treatment market exhibited an average growth of 4.8% in 2020 as compared to 2019.
Sickle Cell Disease (SCD) is an inherited disorder causing diseases such as hemoglobin sickle cell disease, hemoglobin SS disease, and others causing deformation of red blood cells. This leads to early death of cells causing blood shortage and also inhibits the blood flow causing blockage. The disease management is done through medication, blood transfusions, and bone-marrow transplants.
The global sickle cell disease treatment market growth is attributed to the increasing prevalence of SCD, rising awareness regarding the disease, and increasing focus of the key players on the launch of new effective drugs for sickle cell disease treatment.
Lower Donation Bone Marrow Donations and Availability of Donors Hampered Market Growth During the COVID-19 Pandemic
The outbreak of COVID-19 had no impact on the pharmacotherapy segment of the market due to the commercialization of branded pharmacotherapy drugs from 2019-2020.
Moreover, based on revenue, the pharmacotherapy segment in the global market witnessed a growth of 100.1% in 2020 as compared to the prior year.
However, blood transfusion and bone marrow transplant segments experienced a decline in growth in 2020 compared to the prior year due to the reallocation of healthcare resources for COVID-19 treatment. Furthermore, since the number of people opting for sickle cell disease treatment reduced, the market was affected negatively. Moreover, the postponement of non-urgent medical procedures also negatively affected the growth of both segments.
Although the blood transfusion and bone marrow transplant segment experienced a negative COVID-19 impact, it was offset by the new launches in the pharmacotherapy segment. Therefore, the global market witnessed stable growth.
In 2021, the growth of the blood transfusion and bone marrow transplant segments bounced back to normal due to increasing vaccination among the population, implementation of strong COVID-19 guidelines, and the dismissal of travel restrictions.
Request a Free sample to learn more about this report.
Increasing Gene Therapy Adoption Bolstered the Development of Effective SCD Treatments
Gene therapy has emerged as the ultimate cure for various chronic diseases. In the case of hereditary diseases, gene therapy is a revolution that targets the root cause of a disease. With increasing research on the correction of genetic mutation for the treatment of the disease, market players have shifted their R&D focus toward gene therapy.
Similarly, CRISPR Therapeutics and Vertex Pharmaceuticals have been conducting clinical trials on CRISPR-Cas9 gene-edited therapy CTX001. It is currently in phase 3 clinical and is estimated to complete in October 2024. Positive clinical studies on CTX001 suggest that the pipeline candidate can become a blockbuster drug when it is launched in the market. This factor is expected to significantly grow the global sickle cell disease treatment market in the coming years.
Increasing Prevalence along with High Severity Associated with the Disease to Surge the Demand for Effective Treatment Procedures
Sickle cell disease affects millions of people throughout the world. The prevalence of SCD disease has been increasing at a faster pace.
The Vaso-occlusive Crisis (VOCs) is a common painful complication of sickle cell disease in adolescents and adults. It causes acute episodes of severe pain. Patients, including adults and children, need to seek emergency medical care.
Major companies operating in the market have increased their focus on the launch of drugs to reduce the severity of these diseases and treat painful complications associated with them.
The increasing prevalence of SCD and the efficacy of the products for the disease treatment in reducing the chances of VOCs are increasing its adoption among the patient population.
Emergence of New Treatment Modalities to Contribute to Market Growth
Earlier, SCD management only involved blood transfusion and bone marrow transplantation. The increasing prevalence of the disease and rising awareness regarding the disease increased the demand for other effective treatment types.
Major players increased their focus on the launch of new products for the treatment of this disease and to meet demands.
After the launch of Endari few more companies emerged in the market with new products launches, including Oxbryta (Global Blood Therapeutics), Adakveo (Novartis), Zynteglo (bluebird bio Inc.), and PYRUKYND (Agios Pharmaceuticals, Inc.).
Moreover, FDA and EMA are also playing a significant role by providing speedy approval to these products. FDA provides accelerated approval to drugs for serious conditions to fill an unmet medical need based on a result that is reasonably likely to predict a clinical benefit to patients.
The expected launch of new drugs in the forecast period and the rising prevalence of the disease are likely to fuel the market growth.
Limited Availability of Treatment Options for SCD in the Emerging Countries to Limit Market Growth
The pharmacotherapy of sickle cell disease treatment consists of hydroxyurea and a few branded drugs. Hydroxyurea is considered the first line of the disease treatment and is recommended by many healthcare professionals. However, the lack of availability of treatment options in countries and regions across the globe stands out as a restraining factor.
Moreover, blood transfusions for SCD management are also dependent on donor availability. Even if the donors are available, there are chances of inappropriate screening, leading to increased blood transfusion-transmitted infections.
Public and private funding in African countries is insufficient to improve the healthcare facilities and care required by the patients suffering from the disease.
Furthermore, combined with the lack of awareness about the disease among the population in emerging economies, it can limit the global market growth during the forecast period.
To know how our report can help streamline your business, Speak to Analyst
Blood Transfusion Segment to Lead Backed by its Efficiency in Treatment Modality for Stroke Management
Based on treatment modality, the market is segmented into bone marrow transplant, blood transfusion, and pharmacotherapy. The pharmacotherapy segment is further bifurcated into hydroxyurea and branded products. The blood transfusion segment generated the highest revenue in 2021 and is expected to grow at a stagnant CAGR during the forecast period. Blood transfusion is the most efficient treatment method to manage strokes, which is one of the severe symptoms of SCD. The increasing number of episodes of strokes among SCD patients has increased the demand for blood transfusion treatment. This factor is responsible for the segment’s dominance.
Furthermore, the pharmacotherapy segment is expected to grow at the fastest CAGR during the forecast period. The high growth rate of the segment is due to the introduction of new branded pharmacotherapy drugs and increasing government initiatives on early launches of these drugs. Moreover, limited treatment options currently available in the market are also responsible for the segment’s growth in the forecast period. The government supports research activities for sickle cell disease treatment through funding and designations such as orphan drugs, fast track, and priority review, among others. These factors are expected to accelerate the introduction of new branded pharmacotherapy drugs into the market and provide significant momentum to the pharmacotherapy segment.
Hospitals Segment to Dominate Attributable to Rising Prevalence of Patients Visiting Hospitals
On the basis of end-user, the market is segmented into hospitals, specialty clinics, and others.
The hospitals segment accounted for a significant global sickle cell disease treatment market share in 2021. The large share of the segment is attributed to the increasing prevalence of SCD disease and the rising number of hospital admissions for sickle cell disease treatment.
The specialty clinics segment is estimated to grow at a significant CAGR during the forecast period. This segment’s growth is attributable to the increasing number of specialty clinics providing care and sickle cell disease treatment.
The U.S. market generated a revenue of USD 1.05 billion in 2021. The dominance of the market in the country is attributed to better access to SCD treatment, potential pipeline candidates, strong government support, and rising collaborations to improve the treatment of the disease.
The market in Europe accounted for a significant market share in 2021 and is projected to witness considerable growth during the forecast period. The market growth in Europe is attributed to the favorable reimbursement policies, the increasing prevalence of the disease, and increasing market players’ emphasis on the expansion of their offerings in the region.
The rest of the world is expected to expand at a significant CAGR in the projected years. The high market growth in the region is attributed to the highest prevalence of SCD in Africa, the Middle East, South America, and the Mediterranean regions and increasing disposable incomes. Moreover, the increasing awareness about SCD and the strong pipeline of branded drugs are also expected to fuel the market growth in the region.
Companies with Strong Sickle Cell Disease Treatment Sales to Dominate the Competition
Global Blood Therapeutics Inc. (Pfizer Inc.), Novartis AG, and Emmaus Medical, Inc. are the prominent players in the market and captured a considerable global market share in 2021.
Global Blood Therapeutics Inc. (Pfizer Inc.) dominated the market in 2021 and accounted for a significant market share due to the company’s strong sales from Oxbryta for SCD treatment.
Similarly, Novartis AG held a considerable share of the market in 2021 due to increasing focus on partnerships with several government organizations. This partnership may allow the company to address the unmet needs of the patient population. Moreover, the company’s emphasis on the expansion of the availability of its product globally is also responsible for the company’s significant position in the market.
Furthermore, blood transfusion also generated significant revenue accounting for 51.4% of the market value in 2021 due to increasing SCD complications, such as stroke, which can be prevented through blood transfusion therapy.
An Infographic Representation of Sickle Cell Disease Treatment Market
To get information on various segments, share your queries with us
The research report provides a detailed competitive landscape. It includes the prevalence of sickle cell disease and key industry developments such as partnerships, mergers, & acquisitions. Additionally, it focuses on key points such as new product launches in the market. Furthermore, the report covers regional analysis of different segments and company profiles of key sickle cell disease treatment players, including business overview, financial data, and SWOT analysis for each company. Moreover, the report includes market trends and the impact of COVID-19 on the market. The report consists of quantitative and qualitative insights contributing to the market's growth.
ATTRIBUTE | DETAILS |
Study Period | 2018-2029 |
Base Year | 2021 |
Estimated Year | 2022 |
Forecast Period | 2022-2029 |
Historical Period | 2018-2020 |
Unit | Value (USD Billion) |
Segmentation | By Treatment Modality, End-user, and Geography |
By Treatment Modality |
|
By End-user
|
|
By Geography |
|
Fortune Business Insights says that the global market stood at USD 1.73 billion in 2021 and is projected to reach USD 8.75 billion by 2029.
The market is expected to exhibit a CAGR of 21.4% during the forecast period (2022-2029).
The blood transfusion segment is set to lead the market by treatment modality.
The key factors driving the market are the wave of innovation in SCD therapeutics, increasing prevalence of SCD, and the approval of advanced pharmacotherapy drugs to manage the disease.
Global Blood Therapeutics Inc. (Pfizer Inc.), Novartis AG, and Emmaus Medical, Inc. are the top players in the market.
Related Reports